The neuroAD system is based on Neuronix’s patented Non Invasive Cortical Enhancer (NICE™) technology that combines two modalities concurrently. Focused Transcranial Magnetic Stimulation (TMS) is used to stimulate targeted areas of the brain responsible for various cognitive functions that have been impaired by Alzheimer’s disease. This stimulation induces LTP (Long-Term Potentiation), which is associated with learning and memory processes, and makes these areas of the brain more receptive to Cognitive Training. Tailored Cognitive Training targets those same areas of the brain while they are being magnetically stimulated.
The concurrent use of these two modalities has been shown to have a synergistic effect. Not only do patients experience improvement in cognitive and daily function and decision-making; neuroAD treatment potentially modifies the actual course of disease progression.
neuroAD is an investigational device currently not commercially available in the United States.
neuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s Disease in Europe.